Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy

✍ Scribed by Farhang Rabbani; Martin E. Gleave; Christopher M. Coppin; Nevin Murray; Lorne D. Sullivan

• Book ID: 102651595
• Publisher: John Wiley and Sons
• Year: 1996
• Tongue: English
• Weight: 633 KB
• Volume: 78
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/(sici)1097-0142(19960801)78:3<480::aid-cncr15>3.0.co;2-v

✦ Synopsis

BACK(iR0UND.

Recent advances in the therapy of advanced testicular nonseminomatous germ cell tumors (NSGCT) have resulted in increased attention to avoiding doubll-therapy in cases where single modality therapy will suffice. METHODS. Over an 8-year period, 104 patients with Stage I1 and 111 testicular NSGCT received primary chemotherapy. Seventy-nine patients had retroperitoneal lymph nodal metastases, 33 of whom had a radiologic complete response, 43 a radiologic incomplete response, and 3 were not re-evaluated after induction chemotherapy. Thirtynine patients underwent retroperitoneal lymph node dissection (RPLND). The radiologic and pathologic response of the nodes to primary chemotherapy was correlated with tumor burden (lymph node metastasis size 5 2 cm, 2.1-5 cm, 5.1-10 cm, and >10 cm), primary tumor pathology, and prechemotherapy marker levels.

RESULTS.

Larger initial lymph node size, metastases size, the presence of teratoma